-
Kikuko IWANAGA, Noboru TAKAMURA, Yasuyo ABE, Ye ZHAOJIA, Ken SHINZATO, ...
2005 Volume 52 Issue 1 Pages
23-28
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
Sustained and/or episodic hypotension during hemodialysis (HD) is an important clinical issue. Plasma adrenomedullin (AM) is increased in HD patients with sustained hypotension, but little is known about its implications for episodic hypotension. Ghrelin may also contribute to the pathophysiology of hypotension in HD patients. We evaluated plasma levels of AM and total ghrelin in sustained hypotensive (SH; n = 23), episodic hypotensive (EH; n = 30) and normotensive (NT; n = 23) HD patients. In the EH group, the relationship between low blood pressure during HD and circulating levels of AM and ghrelin was also evaluated. Plasma levels of AM were significantly higher in SH (34.3 ± 8.3 fmol/ml, p<0.01) than in NT patients (27.6 ± 5.2 fmol/ml), but not in EH patients (30.8 ± 6.1 fmol/ml). There was no significant difference of plasma total ghrelin in SH (548.1 ± 426.5 fmol/ml) and in EH patients (544.6 ± 174.3 fmol/ml), compared with NT patients (400.0 ± 219.7 fmol/ml). On the other hand, in EH patients, the "suppressed blood pressure ratio" during HD significantly correlated with plasma AM (r = 0.77, p<0.001) and with total ghrelin levels (r = 0.44, p<0.05). Our results suggest that ghrelin, as well as AM, may play an important role as vasodilator local hormones and regulation of blood pressure during HD, especially the occurrence of EH. Further studies are necessary to clarify the implication of these hormones in the control of hypotension during HD.
View full abstract
-
Tetsuo YANAGISAWA, Kanji SATO, Yoshiyuki KATO, Satoru SHIMIZU, Kazue T ...
2005 Volume 52 Issue 1 Pages
29-36
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
When thyrotoxic patients are first seen in an outpatient clinic, it is important to make a differential diagnosis of Graves' disease (GD) and painless thyroiditis (PT). Using the three parameters of total T
3/T
4 ratio, TSH and T-ALP activity, all of which can be obtained within one hour in our hospital, 173 untreated patients with thyrotoxicosis were evaluated for the ratio of each parameter. For GD vs. PT, total T
3/T
4 (ng/μg) ratio (>20), TSH (<0.005 μU/ml) and elevated T-ALP had a likelihood ratio of 2.14, 2.12 and 4.07, respectively. When a patient had all three positive parameters, the likelihood ratio increased to 5.81, which showed effective synergy. These data suggest that, in addition to total T
3/T
4 ratio and TSH value, T-ALP activity is a useful parameter for the rapid differentiation of GD. The lower T-ALP activity seen in PT is probably due to the fact that patients develop less severe thyrotoxicosis or visit hospital earlier than patients with GD. Therefore, the diagnostic accuracy for Graves' disease might be increased by using the three parameters in combination.
View full abstract
-
Kunihiko HANEW, Katsuhiko TACHIBANA, Susumu YOKOYA, Kenji FUJIEDA, Tos ...
2005 Volume 52 Issue 1 Pages
37-43
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
The ratio, clinical characteristics, and therapeutic efficacy of hGH treatment in patients with severe short stature (HtSDS below –4SD) with severe GHD (all peak GH values to provocation tests: below 2 μg/L) were studied. From March 1986 to January 1998, 23,110 patients with idiopathic GH deficiency (IGHD) were registered with the Foundation for Growth Science, Japan. These subjects were divided into 5 groups as follows: Group 1 (G1), all subjects; Group 2 (G2), at least one GH peak to provocative test ≥5 μg/L; Group 3 (G3), 2 μg/L ≤GH peak<5 μg/L; Group 4 (G4), all GH peaks<2 μg/L and HtSDS>–4; Group 5 (G5), all GH peaks<2 μg/L and HtSDS≤–4. The ratio of G5 was 139 patients (0.6%) out of 23,110 patients with IGHD. In G5, there were no significant differences in birth weight, birth length, gestational age and parental height between G2, G3 and G4. However, asphyxia at delivery was more frequent in G5 and G4 than G2 and G3. Chronological age (CA), bone age (BA) and BA/CA ratio at registration were significantly lower in G5 than G2, G3 and G4. Further, the IGF-I SD score in G5 was significantly lower than those in G2 and G3. After hGH treatment, the final height and final height SDS in G5 remained the lowest, while the ΔHtSDS value in G5 was the greatest among G2 to G5 groups. In conclusion, the ratio of severe short stature with severe GH deficiency (G5) is only 0.6% of all IGHD cases. Growth failure in G5 seems to occur after birth, and its etiology in G5 seems to be different from that of patients with other forms of IGHD. Early diagnosis and hGH treatment are needed to attain better final height.
View full abstract
-
Yasuhiko SAIKI, Takashi ISHIHARA, Katsuji IKEKUBO, Toru MORI
2005 Volume 52 Issue 1 Pages
45-55
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
We analyzed TSH receptor (TSHR) effects, both binding and thyroid-stimulation, of TSH and Graves' IgG. A new TRAb assay system utilizes rhTSHR coated tubes and is comprised of two step incubation, the first incubation with patient serum followed by a second incubation with
125I-bTSH. We called TRAb measured by this method as hTRAb.
125I-bTSH binding capacity of the tube was found close to saturation at 1 hr with 200 μl of
125I-bTSH. Up to 5 hr of first incubation for hTRAb assay revealed significant increases in all hTRAb activities. hTRAb was not affected by second incubation time or dose of
125I-bTSH. When 1 step incubation with
125I-bTSH and Graves' serum was performed, hTRAb again increased significantly with time. A simple competitive equilibrium model could not be applied to these ligands. Second, Graves' IgG and bTSH were compared for
in vitro thyroid-stimulation sequentially up to 24 hr, measuring cAMP generation from cultured porcine thyrocytes. While bTSH yielded peak cAMP generation by 8 hr, TSAb revealed more cAMP generation by 24 hr than at 8 hr. We concluded that individual Graves' sera contain heterogeneous TRAb of variable avidities, and that slow-acting TRAb, which may lack biological activity, can be detected by prolonged incubation.
View full abstract
-
Tuncay YILMAZLAR, Turkay KIRDAK, Saduman ADIM, Ersin OZTURK, Omer YERC ...
2005 Volume 52 Issue 1 Pages
57-59
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
A 56-year-old woman presented with rapidly enlarging thyroid mass and deep anemia. There was no history of gastrointestinal bleeding, and endoscopic examinations of the gastrointestinal system were normal. Fine needle aspiration cytology from the thyroid nodule was suspicious. After blood transfusion, total thyroidectomy was performed. Postoperative histopathological examination of the specimen revealed hemangiosarcoma of the thyroid. After establishment of the diagnosis chemotherapy was started. But hemoglobin values decreased again and hepatosplenomegaly developed at the second month of surgery. Bone marrow aspiration cytology which was performed demonstrated the same tumoral cells infiltrating bone marrow. The patient died at 12th week after surgery. Thyroid hemangiosarcoma can metastasize to the bone marrow and anemia may be an indicator of the advanced disease. In the differential diagnosis of the anemia, bone marrow metastasis and bone marrow biopsy should be considered in suspected cases.
View full abstract
-
Katsuji IKEKUBO, Megumu HINO, Yasuhiko SAIKI, Cheol SON, Toshio IWAKUR ...
2005 Volume 52 Issue 1 Pages
61-68
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
We described two euthyroid patients with normally functioning goiters, but with persistently undetectable and non-stimulatable TSH levels. Subject 1 was a 64-year-old woman with a large diffuse goiter who has been clinically and biochemically euthyroid without any medication for at least 19 years. Subject 2 was a 31-year-old woman with a small diffuse goiter who has been euthyroid for 4 years. Both patients had persistently undetectable levels of serum TSH, TSH receptor antibodies (TRAb) and thyroid stimulating antibodies (TSAb). Their basal TSH levels were very low and their T
3 responses to TRH were very diminished or absent. In contrast, the basal levels of the other pituitary hormones and their responses to LHRH, GRH and CRH stimulation were all within normal limits in both patients. MRI images of pituitary glands,
123I thyroid uptake, and thyroid scans were normal. Ectopic thyroids were not detected on
99mTcO
4– and
123I total body scans. Factors interfering with the measurement of TSH were excluded by recovery studies. In subject 1 a T
3-suppression test was positive and a perchlorate discharge test was negative. In subject 2 a T
3-suppression test was negative. Euthyroid Graves' disease, subclinical hyperthyroidism, destructive thyroiditis, thyrotoxicosis of extrathyroid origin, central hypothyroidism, and nonthyroidal illness were all ruled out by these observations. These results suggest that an unknown factor, such as thyrostimulin, but not TSH or TSAb, stimulates the thyroid and maintains euthyroidism, and may have a role in the regulation of the hypothalamus-pituitary-thyroid axis.
View full abstract
-
Cheolyoung PARK, Eunhee KIM, Sookjin SOHN, Inmyung YANG, Gwanpyo KOH, ...
2005 Volume 52 Issue 1 Pages
69-74
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
Thyrotropin-releasing hormone (TRH)-stimulated thyroid stimulating hormone (TSH) response in normal subjects is suppressed by oral glucose administration. Pharmacologic studies indicate that this suppressive action of glucose is mediated by an increase in hypothalamic somatostatin (SRIH) tone. Since activation of the β-adrenergic system also suppresses basal TSH secretion by enhancing SRIH release we sought to determine whether isoproterenol alters the suppression of TRH-induced TSH response induced by the stimulation of glucose. Four tests were performed in seven healthy young men: Test 1: 200 μg TRH (iv) at 0 min; Test 2: 100 g oral glucose at –30 min and TRH at 0 min; Test 3: TRH at 0 min with isoproterenol (0.012 μg/kg, iv) infused continuously; Test 4: oral glucose at –30 min, TRH at 0 min with isoproterenol infused continuously. Pretreatment with glucose significantly suppressed TRH-induced TSH secretion. Isoproterenol infusion also suppressed the TRH-induced TSH secretion, but it did not enhance the inhibitory action of glucose on TSH secretion. The degree of suppression induced by glucose was significantly higher than that achieved by isoproterenol. These data suggest that combined administration of glucose and isoproterenol does not exhibit synergistic inhibitory actions on TRH-stimulated TSH secretion, and that the glucose-TRH test could be used for the evaluation of the hypothalamic somatostatinergic activity.
View full abstract
-
Yoshiaki YAMANO, Kenji OHYAMA, Masanori OHTA, Tomoaki SANO, Akishige R ...
2005 Volume 52 Issue 1 Pages
75-81
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
We have cloned a gene which is specifically expressed at the stage of sexual maturation in the rat testis by means of differential display, and have named it spermatogenesis-related factor-2 (SRF-2). Testicular expression was first detected at 5 weeks of age, and its level of the expression increased up to 7 weeks, and was maintained even at 63 weeks. Its cDNA was 2,789 bp in length and encoded an open reading frame of 718 amino acids. This gene was mainly expressed in the spermatocyte, judging from the result of
in situ hybridization. The hypothetical gene product had a motif highly homologous with RabGAP/TBC protein. Taken together, this gene is considered to have some important functions for meiosis. The gene expression was significantly decreased by treatment with TCDD, a candidate endocrine disruptor, when administered to male rats of the nursling period. Body weight and testis weight were decreased by the treatment, but even then the sperm concentration in cauda epididymis was not changed significantly. SRF-2 gene may be a promising biomarker to construct a detection system of uncertain endocrine disruptors.
View full abstract
-
Shun SONEDA, Maki FUKAMI, Masatoshi FUJIMOTO, Tomonobu HASEGAWA, Yasus ...
2005 Volume 52 Issue 1 Pages
83-88
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
The prevalence of undermasculinized external genitalia has increased in several countries including Japan, and this phenomenon has primarily been ascribed to the deleterious effects of environmental endocrine disruptors such as dioxins. To examine a possible role of the genetic susceptibility to dioxins in the development of micropenis (MP), we studied the Arg554Lys polymorphism of the gene for aryl hydrocarbon receptor (
AHR) and the Pro185Ala polymorphism of the gene for aryl hydrocarbon receptor repressor (
AHRR), in 73 boys with MP (34 boys with mild MP from –2.1 to –2.5 SD and 39 boys with severe MP below –2.5 SD) and 80 control males (50 boys and 30 fertile adult males). The allele and genotype frequencies of the
AHR polymorphism were comparable between the two groups of males, but those of the
AHRR polymorphism were significantly different, with the Pro allele and the Pro/Pro genotype being more frequent in boys with MP than in control males (
P-value: 0.0029 for the allele frequency and 0.011 for the genotype frequency). In addition, both polymorphisms were comparable in the allele and genotype frequencies between boys with mild MP and those with severe MP and between control boys and control fertile adult males. The results suggest that the
AHRR Pro185Ala polymorphism may constitute a susceptibility locus for the development of MP in response to dioxins.
View full abstract
-
Alpaslan TUZCU, Mithat BAHCECI, Deniz GOKALP, Yekta TUZUN, Kemal GUNES
2005 Volume 52 Issue 1 Pages
89-94
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
The ssociation between coronary heart disease and subclinical hypothyroidism (SCH) is unclear. We aimed to determine hs-CRP concentrations in patients with SCH. Seventy-seven patients (age 34.6 ± 13.7 yr) with SCH (TSH >4.2 μIU/ml and serum free thyroxine level between 0.932–1.71 ng/dL), and 80 control subjects (age 33.9 ± 13.3 yr) were studied. Thyroid hormones, C-reactive protein, insulin, glucose, total, HDL, LDL and VLDL-cholesterol levels and HOMA-IR index were also determined. TSH levels of SCH group were higher than control (7.4 ± 2.9 and 1.55 ± 0.78 μIU/ml, respectively, p = 0.0001). However, FT4 levels were lower than control subjects (1.18 ± 0.22 ng/dL and 1.38 ± 0.26, respectively, p = 0.001). Serum hs-CRP levels of subjects with SCH were higher than control subjects (4.2 ± 0.8 mg/l and 1.05 ± 0.3 mg/l respectively, p = 0.0001). Insulin levels of SCH group were higher than control (8.5 ± 4.3 μU/ml and 7.1 ± 3.1 μU/ml respectively, p<0.02) but, Homa-IR levels of the two groups were not different. Mean total and LDL-cholesterol levels of SCH group were higher than control (p = 0.01 and p<0.02). We also found a positive correlation between hs-CRP levels and insulin (r = 0.362, p = 0.002 in men, r = 0.358, p = 0.0001 in women), TSH (r = 0.611, p = 0.0001 in men, r = 0.411 p = 0.0001 in women), and prolactin (r = 0.340, p = 0.01 in men r = 0.553, p = 0.0001 in women). Conclusions: Patients with SCH, irrespective of gender, have higher serum hs-CRP, insulin, total and LDL-cholesterol levels than healthy subjects. 2- High hs-CRP level, and thereby low grade inflammation may be associated with fasting hyperinsulinemia before insulin resistance becomes evident in patients with SCH.
View full abstract
-
Kumiko HAMANO, Mariko INOUE
2005 Volume 52 Issue 1 Pages
95-101
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
Pulse wave velocity (PWV) is known to represent arterial stiffness and is established as a marker for cardiovascular risk and a prognostic factor for mortality in the case of chronic renal failure or hypertension. The application of an automated apparatus for measuring brachial-ankle pulse wave velocity (baPWV) has made PWV measurement non-invasive, easier to screen for cardiovascular risk and as a result, baPWV measurements have become widely applied in clinical practice in recent years. We assessed the baPWV in 7 flank hypothyroidism patients and 28 subclinical hypothyroidism patients. In comparison with age matched healthy controls, 3 hypothyroid patients had advanced values and by replacement therapy, all 7 subjects showed improvement in their baPWV values (1531.2 ± 242.7 to 1330.2 ± 208.6 cm/s, p<0.05). In 28 subclinical hypothyroid subjects, 71% also had accelerated baPWV values for their age. Ten subjects (36% of all) had neither hypertension, hyperlipidemia, diabetes nor were taking any medication, and yet 8 patients out of 10 showed advanced baPWV values compared to age matched mean values. The baPWV was not correlated to TSH or total cholesterol levels, and was associated with only age and blood pressure (p = 0.01, <0.001, respectively), which are widely demonstrated as the characteristics for baPWV. In two subclinical hypothyroid subjects, who were normotensive and had no dyslipidemia, thyroxine treatment was performed and the baPWV decreased with unchanged blood pressure and total cholesterol levels. We concluded that the arterial wall stiffness tends to be increased in both overt and subclinical hypothyroid patients, and an appropriate treatment could reverse the abnormalities. It is possible that the initiation of adequate treatment in subclinical hypothyroidism may reduce the cardiovascular risk.
View full abstract
-
Huy Anh TRAN, Nikolai PETROVSKY
2005 Volume 52 Issue 1 Pages
103-109
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
Cushing's syndrome and its various aetiologies is a markedly difficult diagnosis to make given its subtle signs, sometime cyclical nature, and the lack of a single definitive diagnostic test. Although a great variety of diagnostic tests have been developed to assist in the diagnosis, even with the best clinical acumen, biochemistry and medical imaging the diagnosis can remain elusive. The long low and high dose oral dexamethasone suppression test is cumbersome, costly and often requiring an extended inpatient stay. The utility of the dexamethasone suppression test would be greatly enhanced if it could be performed as a short outpatient procedure. In this study we sought to confirm and refine the clinical utility of the high dose 4 mg intravenous dexamethasone suppression test as an alternative diagnostic test for Cushing's syndrome. There were a total of 31 subjects: 8 patients with proven pituitary Cushing's disease, 3 with primary adrenal tumors, 10 with pseudo-Cushing's syndrome and 10 healthy controls. All subjects with pseudo-Cushing's syndrome suppress serum cortisol at +5 and at +24 hours. In subjects with pituitary Cushing's disease, 7 out of 8 (88%) had serum cortisol suppressed at +5 hours but rebounded at +24 hours to at least 70% of the original serum level. Primary adrenal tumors showed a pattern of non-suppression throughout. The 4 mg intravenous dexamethasone suppression test is excellent in ruling out pseudo-Cushing's syndrome. This test is much simpler and more convenient than the
oral dexamethasone suppression test in confirming clinical suspicion of pituitary Cushing's disease.
View full abstract
-
Yasuhiro NAKAMURA, Takashi SUZUKI, Tsukasa INOUE, Chika TAZAWA, Takuya ...
2005 Volume 52 Issue 1 Pages
111-115
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
3β-hydroxysteroid dehydrogenase (3β-HSD) is known to be involved in steroid production and/or metabolism and to be expressed in many tissues including adrenal cortex. Expression of this enzyme has also been elucidated in human cardiovascular system but its details remain largely unknown. Therefore, in this study, we examined the status of 3β-HSD in postmortem human aorta utilizing RT-PCR and immunohistochemical analysis. Both mRNAs and immunoreactivity for the enzyme were detected predominantly in female aorta, and in those with mild atherosclerotic changes. In addition, immunohistochemical study demonstrated that immunoreactivity for 3β-HSD was detected in vascular smooth muscle cells (VSMCs) of aorta. These findings all indicated that steroidogenesis via 3β-HSD may occur in VSMCs of human aorta, possibly related to gender differences and/or the degree of atherosclerosis.
View full abstract
-
Hiroshi NISHIOKA, Jo HARAOKA, Tamotsu MIKI
2005 Volume 52 Issue 1 Pages
117-123
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
Functioning pituitary adenomas may exhibit spontaneous remission after pituitary apoplexy usually in association with hypopituitarism. We report two patients who presented with sudden headache and double vision, showed a ring-enhanced sellar tumor on MRI, underwent transsphenoidal surgery that revealed a coagulation necrotic adenoma without massive hemorrhage, and showed normal pituitary function after the surgery. Definitive diagnoses were made based on immunohistochemistry of the necrotic cells. The findings were consistent with the presence of selective infarct of a GH adenoma and a prolactinoma that had led to remission of acromegaly and menstrual disturbance, respectively, without pituitary insufficiency. In contrast to hemorrhagic apoplexy, infarctive apoplexy tends to affect only the tumor and thus presents with mild symptoms and lack pituitary deficiencies.
View full abstract
-
Kazunori ARITA, Kaoru KURISU, Atsushi TOMINAGA, Kazuhiko SUGIYAMA, Kun ...
2005 Volume 52 Issue 1 Pages
125-130
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
Recent criteria for cure of acromegaly require normalization of the insulin-like growth factor (IGF-1) level. A retrospective study was conducted to assess postoperative sequential changes in the blood IGF-1 level and to determine the appropriate timing for endocrinologic assessment of the effect of surgery. Blood IGF-1 levels were measured at least 3 times (4.9 ± 2.0, mean ± SD) during the first postoperative year in 36 acromegalic patients whose glucose tolerance test results, obtained 3 months after surgery, showed the growth hormone level to be suppressed to under 1 ng/mL. Postoperative IGF-1 parameters,
i.e. the actual IGF level and %IGF-1 compared to the nadir during the first postoperative year, rapidly decreased during the first 2 postoperative weeks and then slowly declined over the next 2 weeks. They reached a plateau (stable nadir) during the 2nd postoperative month. Assessment of the postoperative endocrinologic status should be delayed at least one month after surgery in acromegalic patients.
View full abstract
-
Mariko MURASE, Tsuguo UEMURA, Mengge GAO, Mae INADA, Toshiya FUNABASHI ...
2005 Volume 52 Issue 1 Pages
131-137
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
In order to compare the mechanism for the down regulation of the mRNA expression of pituitary receptors induced by GnRH antagonist (GnRHant) to that by GnRH agonist (GnRHa), we examined the effects of GnRHant (Cetrorelix, 333 μg/kg/day), GnRHa (leuprolide depot, 333 μg/kg), and GnRHant combined with GnRHa on LH response to exogenous GnRH, pituitary LH content, LHβ subunit mRNA, and GnRH receptor (GnRH-R) mRNA levels at 2, 5, 24, 72 hours, and 7 days after the treatment in ovariectomized rats. GnRHant significantly decreased serum LH, the LH response of the pituitary to exogenous GnRH, and the pituitary LH content compared to the control treatment, though GnRHa significantly increased serum LH. GnRHant with GnRHa significantly diminished the GnRHa-induced flare-up phenomenon. GnRHant significantly decreased LHβ mRNA and GnRH-R mRNA levels, but the magnitude of the decrease in these mRNA levels by GnRHant was significantly less than those by GnRHa until 72 hours following treatment. Prolonged treatment of GnRHant caused a marked inhibition of LHβ mRNA and GnRH-R mRNA expression, similar to that caused by GnRHa. Combination treatment with GnRHa and GnRHant was demonstrated to decrease LHβ mRNA and GnRH-R mRNA levels as much as GnRHa alone and GnRHant alone over 7 days of the treatment. The present study showed differences between GnRHant and GnRHa treatment in the reduction of GnRH-R mRNA levels up to 72 hours after the treatment, and indicated that the suppression of GnRH-R mRNA by GnRHant was the maximal by GnRHa 7 days after the treatment because more profound suppression was not observed upon additional treatment with GnRHa. The findings in the present study support the hypothesis that the mechanism by which GnRHant leads to down-regulation of the mRNA expression of pituitary receptors is similar to that of GnRHa.
View full abstract
-
Wen-Ko CHIOU, Jen-Der LIN, Hsiao-Fen WENG, Yung-Chun OU, Thu-Hua LIU, ...
2005 Volume 52 Issue 1 Pages
139-148
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
Metabolic syndrome is a common disorder in Taiwan. For this study 431 subjects were randomly selected from visitors to the Department of Health Management. Blood pressure, blood glucose, lipid, uric acid levels and anthropometric measurements with immunoreactive insulin (IRI) and leptin levels were all correlated. We randomly selected 431 subjects who visited the Department of Health Management. Whole body three-dimensional (3-D) laser scanner scans were employed for the anthropometric measurements. The metabolic index (MI) was designed using anthropometric parameters. Of the 431 subjects, 50% had displayed a body mass index (BMI) equal to or exceeding 25 kg/m
2. Pearson correlation coefficient and multiple regression analysis revealed that MI constituted another index for correlating metabolic parameters by comparing MI with BMI and waist circumference to hip circumference ratio (WHR). Most data related to metabolic syndrome showed statistically significant differences between high and low IRI groups, comprising uric acid, total cholesterol, fasting plasma glucose, triglyceride, LDL, Chol/HDL ratio, and LDL/HDL ratio. Both IRI and leptin revealed statistical association with BMI, WHR, waist cross section area to hip cross section area ratio (WHAR), and MI in the study. Hypercholesterolemia appeared in 14.6% of the subjects. Elevated low-density lipoprotein (≥130 mg/dL) affected 36.9% of the subjects. In conclusion, MI calculated from 3-D body scanner correlated with many important metabolic risk factors and associated with clinical disorders like DM, hyperlipidemia, hyperuricemia and hypertension.
View full abstract
-
Servet AKAR, Abdurrahman COMLEKCI, Merih BIRLIK, Fatos ONEN, Ismail SA ...
2005 Volume 52 Issue 1 Pages
149-151
Published: 2005
Released on J-STAGE: March 10, 2005
JOURNAL
FREE ACCESS
Thyrotoxic hypokalemic periodic paralysis (THPP) is a rare complication of hyperthyroidism and an uncommon form of hypokalemic periodic paralysis. Its differentiation of more common forms of periodic paralysis is important because aggressive treatment can place the patient at risk for rebound hyperkalemia. Treatment of the underlying thyroid dysfunction cures the muscle symptoms. Here we describe a 37-year-old Turkish male with THPP whose paralysis attack recurred soon after administration of radioactive iodine.
View full abstract